SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
乌托邦
Lv5
840 积分
2021-12-16 加入
最近求助
最近应助
互助留言
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
1天前
已完结
Efficacy and safety of re-challenging 160 mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: A real-world study
1个月前
已完结
Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial
1个月前
已完结
Overall Survival From the EORTC LCG-163 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions
1个月前
已完结
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC
1个月前
已完结
Translational Insights and Overall Survival in the U31402-A-U102 Study of Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC
2个月前
已完结
Immune heterogeneity in small-cell lung cancer and vulnerability to immune checkpoint blockade
2个月前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
2个月前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
2个月前
已关闭
没有进行任何应助
感谢,么么哒
1天前
感谢,帮大忙了
1个月前
感谢,速度真快
1个月前
点赞,速度真快
1个月前
感谢,帮大忙了
2个月前
感谢,速度真快
2个月前
感谢,速度真快
2个月前
感谢,速度真快
2个月前
速度真快,帮大忙了
3个月前
感谢,点赞
3个月前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论